Previous 10 |
Sector Technicals Last week, the XBI (SPDR Biotech ETF) and IBB (iShares Nasdaq Biotechnology ETF) fell 4.16% and 3.38%, respectively. When markets have a tough week, take advantage of this opportunity to scan for stocks that are swimming upstream against the tide. Data by YCharts ...
InflaRx (NASDAQ: IFRX ): FY GAAP EPS of -€2.60. More news on: InflaRx N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1 Start of three Phase II trials for IFX-1 in two serious inflammatory diseases Expansion of our operations along a number of fronts Cash and cash equivalents and current financial ...
Third autoimmune disease being evaluated with IFX-1 Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers JENA, Germany, Feb. 27, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing a...
JENA, Germany, Feb. 14, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that Mr. Richard Brudnick has been appointed as interim Non-Executive Director to t...
Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment Baseline characteristics from ongoing phase IIb SHINE trial in line with expectations; on track for topline results Q2 2019 JENA, Germany and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWI...
Editor's note: Seeking Alpha is proud to welcome SwissBioT as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Over the last s...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...